Data Epilepsy Safety Therapy 
MMJ Recs
NOVEMBER 17, 2023
Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. MMJ is known for its efficacy in treating various medical issues, including chronic pain, epilepsy, multiple sclerosis, and more. It oversees licensing, quality control, and patient access.
Cannabis Law Report
AUGUST 10, 2021
GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. TSC is typically diagnosed in childhood. (5)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 11, 2021
The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.
Canna Law Blog
DECEMBER 16, 2021
Psilocybin research license, which will allow the testing potency, conducting clinical investigations, researching efficacy and safety, and agricultural research. Psilocybin therapy is a breakthrough avenue for providing people with treatment for these ailments.
Veriheal
APRIL 11, 2022
We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. Absolutely.”
Healer
JUNE 28, 2019
Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Adopted Name for Sativex , which does not yet have an INN), a novel cannabinoid formulation, is undergoing investigation as add-on therapy for this population. Nabiximols (Nabiximols is the U.S. Abstract: Medical Study .
Cannabis Law Report
NOVEMBER 16, 2021
Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. a driver of chronic inflammation.
Expert insights. Personalized for you.
98 
Let's personalize your content